Liver cancer patients in India seeking advanced treatments including CAR-T cell therapy now have expanding access pathways through specialized oncology centers, clinical trial networks, and multidisciplinary tumor boards that evaluate eligibility for investigational therapies and established immunotherapy protocols. TL;DR India launched its first indigenous CAR-T therapy NexCAR19 in 2026, showing promising results in leukemia and lymphoma, though liver cancer applications rem

🧠 TL;DR Daratumumab is a CD38-targeted immunotherapy used in multiple myeloma and amyloidosis Not every patient needs it immediately-timing is critical Infusion reactions can occur in up to 50% patients initially, but are manageable It interferes with blood tests (Coombs test & protein electrophoresis) Dose does NOT need adjustment in kidney failure or dialysis Cost is typically ₹2–3 lakh/month, but varies due to support programs Many patients consult me to decide whether th